Jazz Pharmaceuticals plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Renée D. Galá
- Full Time Employees
- 2,890
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Waterloo Exchange Dublin DU Ireland D04 E5W7
- IPO Date
- Jan 18, 2012
- CIK
- 0001232524
- Website
- jazzpharma.com
- Similar Companies
- Business
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ), headquartered in Dublin, Ireland and founded in 2003, develops and commercializes innovative biopharmaceutical products for serious diseases with significant unmet needs, primarily in neuroscience and oncology; its core portfolio includes Xywav and Xyrem (sodium oxybate formulations) for cataplexy and excessive daytime sleepiness in narcolepsy, Epidiolex (cannabidiol oral solution) for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, Defitelio (defibrotide) for severe hepatic veno-occlusive disease post-hematopoietic stem-cell transplantation, Rylaze (asparaginase erwinia chrysanthemi recombinant) for acute lymphoblastic leukemia, Vyxeos (daunorubicin and cytarabine liposome injection) for therapy-related acute myeloid leukemia and newly diagnosed acute myeloid leukemia, Zepzelca (lurbinectedin) for metastatic small cell lung cancer, Modeyso (vosoritide) for achondroplasia in pediatric patients, and Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer; products are marketed in nearly 75 countries across North America, Europe, and select international markets including Australia, Israel, Japan, Canada, and parts of the Middle East and Latin America. Recent developments include FDA approval of Ziihera (zanidatamab-hrii) in November 2024 for biliary tract cancer with ongoing pursuits in HER2-positive breast cancer, a March 2025 definitive agreement to acquire Chimerix for approximately $935 million to bolster its pipeline, an August 2025 exclusive licensing agreement with Saniona for SAN2355 targeting epilepsy and neurological conditions where Jazz leads global development and commercialization, a February 2024 deal with Redx Pharma acquiring global rights to a KRAS inhibitor program for up to $880 million, and a October 2025 research collaboration with Iambic Therapeutics on AI-driven drug discovery. The company maintains manufacturing facilities in Ireland, England and Italy, with significant operations in Palo Alto, Philadelphia, Oxford and Cambridge.
Company News
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Boston Trust Walden Corp
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View
4 Biotech Stocks Seeing Unusual Options Volume Today
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
Jazz Pharmaceuticals Q3 Earnings Call Highlights
Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates
Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Jazz Pharmaceuticals PLC $JAZZ Position Lifted by CWA Asset Management Group LLC
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?
Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Financial Comparison: Jazz Pharmaceuticals (NASDAQ:JAZZ) vs. vTv Therapeutics (NASDAQ:VTVT)